Screening protocols call for CTA imaging of blunt trauma patients with risk factors for TCVI, such as cervical spine injuries and skull base fractures. Screening of asymptomatic patients is somewhat controversial [38], as some data indicates that a significant number of ischemic strokes due to TCVI occur prior to diagnosis [2, 43], and that asymptomatic TCVI lesions may carry a relatively low risk of subsequent stroke, particularly when some

variety of antithrombotic therapy is used. Thus, the situation with extracranial TCVI may be analogous to extracranial atherosclerotic disease, PLX-4720 in that asymptomatic lesions carry a much more benign prognosis than symptomatic lesions. Differentiation in outcomes and management options between symptomatic and asymptomatic TCVI lesions is fertile ground for future investigation. Endovascular treatment with stenting and/or embolization was the preferred method of treatment for 7.5% of the respondents overall, and was most popular among neurosurgeons (10.7%), compared

to other specialists. The use of endovascular techniques in the management of patients with TCVI has been reported with increasing frequency in recent years [16, 23–26, 44–49]. However, compared to the other issues surrounding TCVI, the actual clinical benefit of endovascular FDA-approved Drug Library mouse treatment remains the least well defined, underscoring the need for prospective clinical investigation. Responses to the survey questions varied considerably by specialty. Differences in opinion between specialties were significant for estimated case volume, preferred imaging, preferred treatment, and the management of asymptomatic lesions. These differences likely reflect standards of training within each field, clinical perspectives, NF-��B inhibitor experience, and philosophies within individual disciplines. It is not surprising that trauma surgeons see a large volume of TCVI cases and that CTA is their preferred method of imaging, since CT is currently widely used for imaging of trauma patients. Similarly, the observation that the majority (56.9%) of vascular

surgeons prefer anticoagulation for treatment – more than any other specialty – may parallel practice guidelines for the treatment of other problems commonly encountered by vascular surgeons, such as peripheral arterial disease [50]. It is less Erythromycin clear why neurosurgeons, trauma surgeons, and general surgeons are more likely to use endovascular techniques to treat clinically silent TCVI lesions than vascular surgeons, neurologists, and interventional radiologists. The care of TCVI patients, particularly those with polytrauma, does typically involve the participation of multiple specialists. The large practice variation found by this survey highlights the utility of involving multiple specialties in future clinical trials of TCVI, and to include multiple specialties in the formulation of future practice guidelines.